KPC Pharmaceuticals Inc
SSE:600422

Watchlist Manager
KPC Pharmaceuticals Inc Logo
KPC Pharmaceuticals Inc
SSE:600422
Watchlist
Price: 17.03 CNY -1.73% Market Closed
Market Cap: 12.9B CNY
Have any thoughts about
KPC Pharmaceuticals Inc?
Write Note

KPC Pharmaceuticals Inc
Long-Term Debt

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

KPC Pharmaceuticals Inc
Long-Term Debt Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Long-Term Debt CAGR 3Y CAGR 5Y CAGR 10Y
KPC Pharmaceuticals Inc
SSE:600422
Long-Term Debt
ÂĄ172.5m
CAGR 3-Years
11%
CAGR 5-Years
8%
CAGR 10-Years
22%
H
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
Long-Term Debt
ÂĄ104.5m
CAGR 3-Years
9%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
Long-Term Debt
ÂĄ158.1m
CAGR 3-Years
12%
CAGR 5-Years
N/A
CAGR 10-Years
-6%
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
Long-Term Debt
ÂĄ58.3m
CAGR 3-Years
5%
CAGR 5-Years
N/A
CAGR 10-Years
19%
Yunnan Baiyao Group Co Ltd
SZSE:000538
Long-Term Debt
ÂĄ195.6m
CAGR 3-Years
43%
CAGR 5-Years
118%
CAGR 10-Years
42%
S
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
Long-Term Debt
ÂĄ192.6m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

KPC Pharmaceuticals Inc
Glance View

Market Cap
12.9B CNY
Industry
Pharmaceuticals

KPC Pharmaceuticals Inc., founded in 1951, has cultivated a strong presence in the pharmaceutical industry, rooted in the rich herbal traditions of China. With its headquarters strategically located in Yunnan, a region renowned for its vast biodiversity, KPC leverages this unique advantage by integrating indigenous herbal knowledge into modern pharmaceuticals. The company has carved a niche for itself primarily through the production and distribution of traditional Chinese medicine. This approach not only honors the cultural heritage of its origins but also allows the company to capitalize on a growing global demand for alternative and complementary medical treatments. The blend of traditional herbal medicine and cutting-edge pharmaceutical practices forms the backbone of its business model, enabling KPC to sustain substantial revenue through both local and international markets. Diversification is a cornerstone of KPC Pharmaceuticals' strategy. Beyond its traditional medicines, the company has aggressively pursued research and development in the biopharmaceutical sector. This move has expanded its product offerings to include chemical drugs, biotechnology, and over-the-counter products, broadening their appeal to a more extensive clientele. The continuous investment in R&D has led to the development of innovative treatments for ailments such as cardiovascular diseases, cancer, and other chronic illnesses. Additionally, KPC's robust sales network encompasses hospitals, pharmacies, and other healthcare institutions, ensuring widespread distribution and accessibility of its products. Through this diversified portfolio and strong distribution channels, KPC Pharmaceuticals continues to thrive by meeting the evolving needs of the healthcare industry while maintaining its commitment to quality and efficiency.

Intrinsic Value
24.27 CNY
Undervaluation 30%
Intrinsic Value
Price

See Also

What is KPC Pharmaceuticals Inc's Long-Term Debt?
Long-Term Debt
172.5m CNY

Based on the financial report for Sep 30, 2024, KPC Pharmaceuticals Inc's Long-Term Debt amounts to 172.5m CNY.

What is KPC Pharmaceuticals Inc's Long-Term Debt growth rate?
Long-Term Debt CAGR 10Y
22%

Over the last year, the Long-Term Debt growth was 18%. The average annual Long-Term Debt growth rates for KPC Pharmaceuticals Inc have been 11% over the past three years , 8% over the past five years , and 22% over the past ten years .

Back to Top